Temblador-Barba I, Delgado-Alonso EM, Toribio-García M, Martínez-Campillo L, Molina-Leyva I, Martínez-Jiménez M. Update on the management of vasoproliferative tumour.
Arch Soc Esp Oftalmol (Engl Ed) 2018;
93:350-353. [PMID:
29459169 DOI:
10.1016/j.oftal.2018.01.005]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Revised: 01/08/2018] [Accepted: 01/10/2018] [Indexed: 06/08/2023]
Abstract
CASE REPORT
Here we report a 19-year-old female patient who presented a vasoproliferative tumour. It caused complications, such as epiretinal membrane, macular oedema, vitreous haemorrhage, and exudative retinal detachment. The patient was treated with 3 injections of intravitreal bevacizumab, an intravitreal dexamethasone implant, tocilizumab, and double freeze-thaw cryotherapy.
DISCUSSION
Therapeutic options are: observation, if it is small, if it is a peripheral lesion, and if there seems to be no threat to vision. If it requires treatment, laser photocoagulation, intravitreal bevacizumab, trans-conjunctival cryotherapy, transpupillary thermotherapy, photodynamic therapy, brachytherapy plaques and surgery are the different options available. Recently, tocilizumab and intravitreal dexamethasone implants have been reported to be beneficial.
Collapse